NovaBay Pharmaceuticals Valuation
| NBY Stock | USD 0.61 0.01 1.61% |
NovaBay Pharmaceuticals is undervalued. NovaBay Pharmaceuticals secures a last-minute Real Value of $1.37 per share. The latest price of the firm is $0.61. Our model forecasts the value of NovaBay Pharmaceuticals from analyzing the firm fundamentals such as Return On Equity of -2.74, profit margin of (0.73) %, and Current Valuation of 3.45 M as well as examining its technical indicators and probability of bankruptcy.
Undervalued
Today
Please note that NovaBay Pharmaceuticals' price fluctuation is dangerous at this time. Calculation of the real value of NovaBay Pharmaceuticals is based on 3 months time horizon. Increasing NovaBay Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since NovaBay Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of NovaBay Stock. However, NovaBay Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.61 | Real 1.37 | Hype 0.6 |
The intrinsic value of NovaBay Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence NovaBay Pharmaceuticals' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of NovaBay Pharmaceuticals helps investors to forecast how NovaBay stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of NovaBay Pharmaceuticals more accurately as focusing exclusively on NovaBay Pharmaceuticals' fundamentals will not take into account other important factors: NovaBay Pharmaceuticals Total Value Analysis
NovaBay Pharmaceuticals is now forecasted to have company total value of 3.45 M with market capitalization of 2.96 M, debt of 2.74 M, and cash on hands of 5.36 M. Please note that company total value may be misleading and is a subject to accounting gimmicks. We encourage investors to carefully check all of the NovaBay Pharmaceuticals fundamentals before making security assessment based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
3.45 M | 2.96 M | 2.74 M | 5.36 M |
NovaBay Pharmaceuticals Investor Information
About 16.0% of the company shares are owned by institutional investors. The book value of NovaBay Pharmaceuticals was now reported as 0.22. The company recorded a loss per share of 74.61. NovaBay Pharmaceuticals had not issued any dividends in recent years. The entity had 1:35 split on the 31st of May 2024. Based on the key indicators related to NovaBay Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, NovaBay Pharmaceuticals is not in a good financial situation at this time. It has a very high probability of going through financial hardship in April.NovaBay Pharmaceuticals Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. NovaBay Pharmaceuticals has an asset utilization ratio of 163.01 percent. This suggests that the Company is making $1.63 for each dollar of assets. An increasing asset utilization means that NovaBay Pharmaceuticals is more efficient with each dollar of assets it utilizes for everyday operations.NovaBay Pharmaceuticals Ownership Allocation
Roughly 83.86 % of NovaBay Pharmaceuticals outstanding shares are held by general public with 0.02 pct. owned by insiders and only 16.12 % by institutional investors.NovaBay Pharmaceuticals Profitability Analysis
The company reported the last year's revenue of 14.73 M. Reported Net Loss for the year was (9.64 M) with profit before taxes, overhead, and interest of 7.87 M.About NovaBay Pharmaceuticals Valuation
Our relative valuation model uses a comparative analysis of NovaBay Pharmaceuticals. We calculate exposure to NovaBay Pharmaceuticals's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of NovaBay Pharmaceuticals's related companies.NovaBay Pharmaceuticals, Inc., a pharmaceutical company, develops and sells eyecare and skincare products in the United States and internationally. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California. Novabay Pharmaceuticals operates under Biotechnology classification in the United States and is traded on AMEX Exchange. It employs 29 people.
NovaBay Pharmaceuticals Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 120.4 K |
Additional Tools for NovaBay Stock Analysis
When running NovaBay Pharmaceuticals' price analysis, check to measure NovaBay Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NovaBay Pharmaceuticals is operating at the current time. Most of NovaBay Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of NovaBay Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NovaBay Pharmaceuticals' price. Additionally, you may evaluate how the addition of NovaBay Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.